Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.

Pascale HubertPatrick RoncaratiStephanie DemoulinCharlotte PilardMarie AncionCelia ReyndersThomas LerhoDiane BruyereAlizee LebeauCoraline RadermeckerMargot MeunierMarie-Julie NokinElodie HendrickOlivier PeulenPhilippe DelvenneMichael Herfs

Published in: Journal for immunotherapy of cancer (2021)

Collectively, we present evidence that extracellular HMGB1 blockade may complement first-generation cancer immunotherapies by remobilizing antitumor immune response.

Keyphrases

immune response
papillary thyroid
dna damage
stem cells
squamous cell
cell cycle
dendritic cells
lymph node metastasis
inflammatory response